For healthcare professionals only
GP Notebook

This promotional website has been developed, organised and funded by Boehringer Ingelheim.​

Focus on: Ramadan

Prior to Ramadan, it is important to undertake medication reviews of your adult patients with type 2 diabetes who wish to fast during this time

Did you know?

In a study of 11,000 Muslims with type 2 diabetes, 79% fasted during Ramadan despite being exempted due to their medical condition 1

Resources to share with patients

Developed by Alia Gilani,
Senior Diabetes Clinical Pharmacist,
Primary Care Sheffield, Sheffield

Alia is a part-time Senior Diabetes Clinical Pharmacist for Primary Care Sheffield, whose interests lie in ethnic inequalities and diabetes. She helped to establish and run a bilingual medication review service in NHS Glasgow in 2002 and received local and national awards for this work. She has chaired the NHS Glasgow Diabetes Ethnicity and Inequalities Group in the past. 

Alia has been running outreach clinics for South Asian people with diabetes for over a decade and was a member of the Diabetes Working Group for the South Asian Health Foundation (SAHF) for 13 years and had the role of Regional Lead and Chief Executive Officer for 2 years. She was the first pharmacist on the Primary Care Diabetes Society (PCDS) and a committee member for 7 years.

Supporting your patients during Ramadan

  • This leaflet, designed for patients, outlines the key considerations a person with diabetes should be aware of when planning to fast during Ramadan
  • Includes a link to a patient video discussing considerations prior to Ramadan fasting

Ramadan fasting: A guide for adults with type 2 diabetes

  • The importance of a pre-Ramadan medication review
  • When a person with diabetes should break their Ramadan fast
  • Diet and exercise advice

Healthcare professional resources

Supporting your patients during Ramadan

  • How to assess the potential risks associated with fasting
  • Conducting pre-Ramadan medication reviews
  • Offering practical advice to adults with type 2 diabetes who wish to fast

The risks of fasting during Ramadan in adults with type 2 diabetes

  • Potential risks for adults with type 2 diabetes wishing to fast during Ramadan
  • Available screening options for this population

Supporting your patients during Ramadan

  • This 2-page fact sheet summarises the steps to take when reviewing adults with type 2 diabetes who wish to observe Ramadan

Reference: Salti I et al. Diabetes Care 2004;27:2306–11

Webinar

Sarah Jarvis

Kevin Fernando

The event starts in:

DAYS
HRS
MIN
SEC

Coming soon

Join our faculty as they discuss the role of clinical inertia in the suboptimal achievement of treatment targets and share practical tips for addressing this topic with your adult type 2 diabetes patients

Prescribing information for Great Britain and Northern Ireland and the Republic of Ireland.

Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:
• monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
• in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control

This promotional website has been developed, organised and funded by Boehringer Ingelheim. Editorial support for this website has been provided by OmniaMed Communications.

Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard (UK) or https://www.hpra.ie/homepage/about-us/report-an-issue (IRE). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) (UK) or 01 2913960 (IRE), Fax: +44 1344 742661, or by e-mail: [email protected].

PC-GB-106628 V5 | December 2023

Prescribing information for Great Britain and Northern Ireland and the Republic of Ireland 

This website is for healthcare professionals in Great Britain, Northern Ireland and Republic of Ireland only.

To continue, please confirm that you are a healthcare professional in Great Britain, Northern Ireland or the Republic of Ireland by clicking below.
Prescribing information for Great Britain and Northern Ireland
Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard (UK) or https://www.hpra.ie/homepage/about-us/report-an-issue (IRE). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) (UK) or 01 2913960 (IRE), Fax: +44 1344 742661, or by e-mail: [email protected].


You are leaving this site.

You are now leaving https://resources.gpnotebook.com/moving-forward-in-type-2-diabetes-management-with-glp-1ras-resource-hub/.
Links to external website are provided as a resource to the viewer.
This website is neither owned or controlled by Novo Nordisk.
Novo Nordisk accepts no responsibility for the content or services of the linked site.